• BX Home
  • Pharmaceutical Industry: [Page 49]

Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more

PHARMACEUTICAL INDUSTRY

The pharmaceutical industry operates under unique circumstances: Estimates of the cost to bring a single new drug to market range from $800 million to $1.2 billion, and on average, a patent’s life remaining upon FDA launch approval is only eight years. Thus, achieving the highest level of performance is critical to pharmaceutical companies. This topic is dedicated to marketing, market research, business operations, and management issues specific to the pharmaceutical industry.

Pharmaceutical Industry is part of Business Exchange, suggested by Ken Rhines. This topic contains 2,138 news and 781 blog items. Read updated news, blogs, and resources about Pharmaceutical Industry. Find user-submitted articles and reactions on Pharmaceutical Industry from like-minded professionals.

Most Active

The most active stories in this topic based on user activity.

Does Lantus (insulin glargine) increase the risk of breast cancer?more

FDA: Boxed warning for Chantix and Zybanmore

If you don’t think there is a trust issue in pharma, then you haven’t ...more

U.S. advisers call for ban of some pain drugs more

Advisors to the FDA recommended banning Vicodin and Percocet.

Particle Sciences and Microfluidics to Share Formulation and Nanotechn...more

Microfluidics, a wholly owned subsidiary of and Particle Sciences Inc have formed a strategic alliance to help...

Glaxo CEO discusses R&D overhaul more

GlaxoSmithKline's chief executive acknowledged on Friday that overhauling its research operation was traumatic.

Teva Is Ready for Major Acquisition, Chief Says more

Teva Pharmaceutical Industries Ltd., which bought Barr Laboratories Inc. for $7.4 billion last year, is ready for...

Sanofi Chief Executive Says U.S. Acquisition Isn’t a Certaintymore

Sanofi-Aventis SA Chief Executive Officer Chris Viehbacher says a U.S. takeover isn’t necessarily in the cards for...

Big Pharma gets green kudos for carbon-trackingmore

Posted on Carbon Offsets Daily, Climate Counts recently released a scorecard for pharma.

Frost & Sullivan predicts shift of big pharma towards biologicsmore

The recent surge in M&A activities, with four in the first half of 2009 alone, cannot solely be attributed to the...

Generic Biotech Drugs: Cure or Quagmire?more

When President Barack Obama spoke to the American Medical Assn. on June 15, he couldn't quite quantify the potential...

Partnerships With CROs: India, China, Latin America and CEE as Clinica...more

India, China, Latin America and CEE as Clinical Trial Destinations As part of our Partnerships with CROs LinkedIn...

FDA Panel Recommends Psych Drugs for Kidsmore

An advisory panel of the Food and Drug Administration said two leading antipsychotic medications should be approved for...

Vaccines Studies open to developing countriesmore

According to an article at Fierce Vaccines, the University of Sienna and Novartis Vaccines and Diagnostics will be...

FTC: 12-14 yrs too long to protect biotech drugsmore

Generic versions of expensive biotechnology drugs would reduce the amount of money spent on health care in the United...

Nissen Argues Blockbusters are Deadmore

The Cleveland Clinic doc is urging the federal government to back the creation of novel treatments.

Merck's Heart Failure Failuremore

The failure of a Merck drug to treat acute heart failure in a large clinical trial raises new questions about the...

Slump Pushing Cost of Drugs Out of Reachmore

Even with the Medicare drug benefit, even with the prevalence of low-cost generics, even with loss-leader discounting...

Sanofi-Aventis Settles Medicaid Price Disputemore

Sanofi-Aventis SA will pay $95.5 million to settle allegations that it overcharged state Medicaid programs for...

More musings on pharma megamergersmore

Pfizer Inc.'s (NYSE:PFE) $68 billion acquisition of Wyeth (NYSE:WYE) and Merck & Co.'s (NYSE:MRK) $41 billion bid...

Forest Laboratories’ Celexa Doesn’t Help Children With Autismmore

Celexa, part of a class of antidepressants widely prescribed for autistic children, didn’t help reduce their repetitive...

Study gauges effect of drugmakers' ads more

A spike in interest in the drug Zelnorm did little to boost prescriptions.

Bristol-Myers looking to swallow Elan in piecesmore

Shares in Dublin-based biotechnology company Elan Corp. (NYSE:ELN) surged Monday in London after The Wall Street...

Will Pfizer's Merger Hurt Innovation?more

01.26.09, 05:30 PM EST With a megamerger that helps earnings but may hurt science, Pfizer makes a Faustian bargain with...

GE Healthcare and Fujifilm team on imagingmore

GE Healthcare, a subsidiary of General Electric Co. (NYSE:GE), and Fujifilm Corp. (NASDAQ:FUJI) have announced a...

Topic Feed: Most active content in Pharmaceutical Industry

Top Sources: Pharmaceutical Industry

  • pharmachemicalscoatings.blogspot.com
  • BusinessWeek
  • bloomberg.com
  • Reuters
  • New York Times
  • srcomblog.wordpress.com
  • Industry Week
  • pharmatching.com
  • send2press.com
  • myharvardnews.com

Most Active Users in this Topic

see all contributors in Pharmaceutical Industry

Featured White Papers

Tweets on this Topic

Post a Job

Jobs in this Topic

Manager, Pharmaceutical Toll Manufacturing Boehringer Ingelheim | St Joseph, MO
Posted: May 5
Account Manager-Addiction Therapy Services-Pharmaceutical Boehringer Ingelheim | Ohio
Posted: May 5
Pharmaceutical Sales Specialist - CC PCOV2 AstraZeneca | Louisville, KY
Posted: May 21
Pharmaceutical Industry Regulatory Attorney RGP | Princeton, NJ
Posted: May 2
Procurement Pharmaceutical Industry RGP | New York, NY
Posted: May 2

Report comment contains invalid characters. ()
cancel
Search Cancel